Triple-negative breast cancer is getting a treatment upgrade — here's what oncologists need to know

Triple-negative breast cancer (TNBC) is one of the most challenging subtypes to treat — but the field is moving quickly. At the 2026 Bridging the Gaps in Breast Cancer Meeting, Dr. Kelsey Natsuhara of UCSF highlighted exciting progress, particularly around novel antibody-drug conjugates (ADCs) entering the neoadjuvant and adjuvant settings, where researchers are asking whether more patients can ultimately be cured.

As these therapies push earlier into treatment, the metastatic setting becomes more complex. Natsuhara noted that sequencing ADCs with the same payload doesn't appear to work well, meaning careful therapy selection is critical. Emerging areas like bispecific ADCs, novel-target ADCs with diverse payloads, and targeted radioligand therapy are also on the horizon.

Key Takeaways:

• Clinical trials should be considered at every point of therapy change for TNBC patients
• More first-line studies are expected as patients treated with the KEYNOTE-522 pembrolizumab + chemotherapy regimen develop metastatic disease
• AI tools are being used to help match patients to available clinical trials
• Academic-community oncology partnerships are being strengthened to improve trial access regardless of patient location
• Correlative lab studies are needed to better understand resistance mechanisms and identify new biomarkers

Why it matters: With the TNBC treatment landscape shifting rapidly, staying ahead of sequencing decisions and trial opportunities is essential for oncologists — and could meaningfully improve outcomes for patients.